TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Follow-Up Questions
What is Transmedics Group Inc (TMDX)'s P/E Ratio?
The P/E ratio of Transmedics Group Inc is 116.3709
Who is the CEO of Transmedics Group Inc?
Dr. Waleed Hassanein is the President of Transmedics Group Inc, joining the firm since 1998.
What is the price performance of TMDX stock?
The current price of TMDX is $122.17, it has increased 0.88% in the last trading day.
What are the primary business themes or industries for Transmedics Group Inc?
Transmedics Group Inc belongs to Health Care industry and the sector is Health Care
What is Transmedics Group Inc market cap?
Transmedics Group Inc's current market cap is $4.1B
Is Transmedics Group Inc a buy, sell, or hold?
According to wall street analysts, 12 analysts have made analyst ratings for Transmedics Group Inc, including 5 strong buy, 7 buy, 4 hold, 0 sell, and 5 strong sell
